Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercialization

By DripPublished Updated

The gist

Diagnostics and informatics are shifting from episodic testing to reimbursed surveillance, from specialist labs to distributed workflows, and from broad claims to FDA-cleared use cases.

This week’s developments

Reimbursement Is Shifting Diagnostics From One-Off Tests to Serial Monitoring

CMS’s latest MolDX LCD makes reimbursed longitudinal surveillance explicit, expanding dd-cfDNA transplant monitoring beyond one-time testing and into repeat-use care pathways. The final policy broadens coverage to kidney, heart, and lung recipients, raises repeat-testing frequency for kidney surveillance from 4 tests in year 1 and 2 per year in years 2–3 to 6 in year 1 and 4 per year in years 2–3, and keeps heart at 12 tests in year 1 while doubling years 2–3 from 2 to 4 tests annually. It also removes the draft’s proposed post-year-3 cap when testing remains clinically useful and separates surveillance from for-cause use through distinct Z-code identifiers and assay-specific billing criteria.

Oncology is moving the same way: NeoGenomics says Medicare now covers RaDaR ST for late-stage solid tumors on immune-checkpoint inhibitors, its third covered indication after HPV-negative head and neck squamous cell carcinoma and a subset of HR+/HER2− breast cancer. The strategic shift is clear: CMS is rewarding serial monitoring, workflow integration, and management-linked utility, not just assay availability. That favors vendors with evidence generation, billing infrastructure, and care-pathway penetration over those selling novelty alone.

How do we capture value in reimbursed serial monitoring programs?

If you operate in this industry

  • Reimbursement now rewards serial monitoring, not one-off assay sales.
  • Build repeat-testing workflows, billing logic, and evidence for longitudinal use—or lose share to vendors already embedded in care pathways.

Sources

If you sell into this industry

  • CMS is paying for monitoring programs, not just test availability.
  • Shift roadmap and GTM toward serial-use evidence, Z-code/billing support, and workflow integration that proves management-linked utility.

If you invest in this industry

  • Coverage is expanding the TAM for monitoring, but only for proven platforms.
  • Favor vendors with reimbursement depth and pathway penetration; novelty-only names face slower adoption and weaker pricing power.

Biomarker Testing Moves Into Front-Line, Distributed Workflows

Recent launches point to diagnostics moving out of centralized, specialist-led labs and into front-line workflows built around self-collection, PCP triage, and peripheral lab deployment. That shift matters because the competitive battleground is no longer assay performance alone; access, logistics, and data integration are becoming the value drivers.

Flatiron’s addition of a large NSCLC biomarker dataset strengthens the evidence layer for trial matching and real-world analytics, while FDA expansion of HER2 testing in gastroesophageal cancer broadens where biomarker decisions can be made. An AI blood test reporting high lung cancer accuracy reinforces the same direction: detection and algorithmic stratification are increasingly bundled. For operators and vendors, the implication is clear: winning will depend on embedding tests into routine care pathways and connecting results to downstream decision support, not just improving analytical sensitivity.

Where will value accrue as biomarker testing decentralizes?

If you operate in this industry

  • Biomarkers are moving into primary care and peripheral workflows.
  • Build for access and integration, not just assay quality; own PCP triage, self-collection, and downstream decision support.

Sources

If you sell into this industry

  • Workflow fit is now as important as analytical performance.
  • Shift roadmap toward deployable, interoperable products that slot into routine care and trial-matching workflows.

If you invest in this industry

  • Value is shifting from test accuracy to distribution and data layers.
  • Favor platforms with workflow reach and real-world data moats; pure assay plays face margin and relevance pressure.

Sources

FDA-Cleared Claims Are Becoming Commercial Moats

Tempus’s ECG-PH and Labcorp’s Lumipulse pTau-217/Beta Amyloid 42 Ratio show how FDA clearance is shifting competition from broad performance claims to tightly defined, deployable use cases. Tempus won 510(k) clearance for AI software that reads standard 12-lead ECGs to flag signs associated with elevated mean pulmonary artery pressure in patients 40 and older with cardiovascular symptoms and no known pulmonary hypertension, creating a new screening and triage workflow. Labcorp’s August 2025 clearance for adults 50+ in specialized care settings with signs or symptoms of cognitive decline is narrower still, and Labcorp has said broader rollout depends on operational readiness and separate payer-specific reimbursement work.

The strategic value is not just regulatory approval; it is intended-use design that makes products easier to order, defend clinically, and embed into care pathways. FDA-backed claims reduce adoption friction, but they also constrain addressable markets, so winners will be those that pair clearance with workflow integration and reimbursement execution. Companion diagnostics go further: they do not merely validate a test, they create pathology demand tied directly to therapy access.

How do cleared use cases change go-to-market and moat strategy?

If you operate in this industry

  • FDA clearance is turning narrow use cases into defensible workflow moats.
  • Build around specific intended uses and reimbursement paths; broad claims won’t win if they can’t be ordered, defended, and embedded.

Sources

If you sell into this industry

  • Cleared claims now sell better than broad performance promises.
  • Shift roadmap and GTM to FDA-backed, workflow-ready use cases; buyers will pay for deployability, not just model accuracy.

Sources

If you invest in this industry

  • Regulatory precision is becoming a commercial moat, not just a checkbox.
  • Favor companies with clearance plus workflow and payer execution; narrow labels can still scale if they unlock repeatable adoption.

Sources

Stay ahead in Diagnostics & Informatics

Get the weekly Diagnostics & Informatics brief in your inbox — the developments, what they mean by vantage, and what to do next.